Journal Article Concurrent chemoradiotherapy for T3-4 and N0-1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia.

Ohno, Tatsuya  ,  Wakatsuki, Masaru  ,  Huy Quoc Thinh, Dang  ,  Thanh Tung, Ngo  ,  Erawati, Dyah  ,  Supriana, Nana  ,  R Beena Devi, C  ,  Kato, Shingo  ,  Thephamongkhol, Kullathorn  ,  Chansilpa, Yaowalak  ,  Joy C Calaguas, Miriam  ,  Xiaoting, Xu  ,  Jianping, Cao  ,  Akhter Banu, Parvin  ,  Chul-Koo, Cho  ,  Karasawa, Kumiko  ,  Nakano, Takashi  ,  Tsujii, Hirohiko

57 ( 1 )  , pp.44 - 49 , 2015-08 , Oxford University Press
The aim of this study was to evaluate the toxicity and efficacy of radiotherapy concurrent with weekly cisplatin for T3-4 and N0-1 nasopharyngeal cancer. Between 2005 and 2010, 70 patients with nasopharyngeal cancer (T3-4 N0-1 M0, World Health Organization Type 2-3) from Vietnam, Indonesia, Malaysia and Thailand were registered. Patients were treated with 2D radiotherapy concurrent with weekly cisplatin (30 mg/m(2)). Neither adjuvant nor induction chemotherapy was given. Ninety-three percent of the patients completed at least four cycles of weekly cisplatin during radiotherapy. The median total doses for the primary tumor and positive lymph nodes were 70 and 66 Gy, respectively. The median overall treatment time of concurrent chemoradiotherapy was 52 days. No treatment-related deaths occurred. Grade 3-4 acute toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of patients, respectively. With a median follow-up time of 52 months for the 40 surviving patients, the 3-year local control, locoregional tumor control, distant metastasis-free survival and overall survival rates were 80%, 75%, 74% and 80%, respectively. In conclusion, the current results illustrate that our concurrent chemoradiotherapy regimen was feasible, but disease control remained insufficient. Further research is encouraged in order to improve clinical outcomes.

Number of accesses :  

Other information